Abstract Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ and γ (PI3K-δ,γ) being developed for treatment of hematologic malignancies. PI3K-δ,γ signaling can promote B-cell proliferation and survival in clonal B-cell malignancies, such as chronic lymphoc...
Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!